Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 3/20 | 0.71 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12649400 | 0.99 | VEGFA (0.69) | VEGFAEGLN1MEN1KMT2AALDH1A1 | |
| SCHEMBL17005932 | 0.87 | VEGFA (0.58) | VEGFAEGLN1MEN1KMT2AALDH1A1 | |
| SCHEMBL17005927 | 0.86 | CYP2D6 (0.60) | VEGFAEGLN1MEN1KMT2AALDH1A1 | |
| SCHEMBL19157495 | 0.84 | VEGFA (0.76) | VEGFAEGLN1MEN1KMT2AALDH1A1 | |
| SCHEMBL17005867 | 0.84 | ALDH1A1 (0.54) | VEGFAEGLN1MEN1KMT2AALDH1A1 | |
| SCHEMBL12650036 | 0.84 | VEGFA (0.50) | VEGFAEGLN1MEN1KMT2AALDH1A1 | |
| SCHEMBL12649390 | 0.83 | MEN1 (0.58) | VEGFAEGLN1MEN1KMT2A | |
| SCHEMBL12598896 | 0.83 | VEGFA (1.00) | VEGFAEGLN1MEN1KMT2AALDH1A1 | |
| SCHEMBL28567341 | 0.82 | VEGFA (0.68) | VEGFAEGLN1MEN1KMT2AALDH1A1 | |
| SCHEMBL16790919 | 0.82 | VEGFA (0.80) | VEGFAEGLN1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| EP-3698794-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | Aerpio Therapeutics, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3603644-A1 | PROLYL HYDROXYLASE INHIBITORS | Aerpio Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-2952192-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-2952192-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20190055198-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2019-02-21 | — | — | US | disclosed |
| US-20190055198-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2019-02-21 | — | — | US | disclosed |
| US-20170298019-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2017-10-19 | — | — | US | disclosed |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158045-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2496236-B1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2013-05-01 | — | — | EP | disclosed |
| EP-2496236-B1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2013-05-01 | — | — | EP | disclosed |
| US-8309537-B2 | Compositions and methods for treating colitis | AERPIO THERAPEUTICS INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298019-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885MEN1 4767/4885 |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | ALPI, SI, SLC10A2 | VEGFA 4546/4885EGLN1 2861/4885MEN1 4063/4885 |
| US-20130158045-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885MEN1 4767/4885 |
| US-20190055198-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885MEN1 4767/4885 |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885MEN1 4767/4885 |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | VEGFA 20/4885EGLN1 8/4885MEN1 4830/4885 |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | VEGFA 20/4885EGLN1 8/4885MEN1 4830/4885 |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885MEN1 4767/4885 |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885MEN1 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.